Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: Results from a Spanish cohort

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 67-71

  Anton, Jordi ^a   Calvo, Inmaculada ^b   Fernández Martin, Julián ^c   Gamir, Mari Luz ^d   Merino, Rosa ^e   Jimenez Treviño, Santiago ^f   Sevilla, Belen ^g   Cabades, Francisco ^h   Bou, Rosa ^a,i   Arostegui, Juan I ^j  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL DO MEIXOEIRO   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^h Hospital de Vinaros   (Spain)

ⁱ Hospital Universitari Parc Taulí   (Spain)

^j INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

more..

Author keywords

Autoinflammatory disorders; Canakinumab; Cryopyrin associated periodic syndromes; Interleukin 1; NLRP3

Indexed keywords

CANAKINUMAB; CARRIER PROTEIN; IL1B PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; NLRP3 PROTEIN, HUMAN;

ABDOMINAL ABSCESS; ACUTE APPENDICITIS; ADOLESCENT; ADULT; AGED; ARTHROPATHY; ARTICLE; CHILD; CINCA SYNDROME; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; GENE; GERMLINE MUTATION; HETEROZYGOTE; HUMAN; INFECTION COMPLICATION; INJECTION SITE REACTION; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NLRP3 GENE; OBSERVATIONAL STUDY; PERCEPTION DEAFNESS; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SOUTHERN EUROPEAN; SPANISH (PEOPLE); UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DOSE CALCULATION; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MULTICENTER STUDY; PHENOTYPE; RISK FACTOR; SPAIN; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DRUG DOSAGE CALCULATIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; PHENOTYPE; REMISSION INDUCTION; RISK FACTORS; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84954598512     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. HOUTEN SM, FRENKEL J, WATERHAM HR: Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol Life Sci 2003; 60: 1118-34.
2. KASTNER DL, BRYDGES S, HULL KM: Chapter 27: Periodic fever syndromes. In: OCHS HD, EDVARD SMITH CI and PUCK JM (Eds.). Primary immunodeficiency diseases. A molecular and genetic approach. 2nd ed. Oxford University Press 2007; p. 367-389.
3. LEVY R, GéRARD L, KUEMMERLE-DESCHNER J et al.; for PRINTO and Eurofever: Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis 2014 Jul 18 [Epub ahead of print] doi: 10.1136/annrheumdis-2013-204991.
4. HOFFMAN HM, MUELLER JL, BROIDE DH, WANDERER AA, KOLODNER RD: Mutations of a new gene encoding a putative pyrin-like protein causes familial cold autoinflamatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 301-5.
5. AKSENTIJEVICH I, PUTNAM CD, REMMERS EF et al.: The clinical continuum of cryopyrinopathies. Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007; 56: 1273-85.
6. AKSENTIJEVICH I, NOWAK M, MALLAH M et al.: De Novo CIAS1 Mutations, Cytokine Activation, and Evidence of Genetic Heterogeneity in Patients with Neonatal-Onset Multisystem Inflammatory Disease (NOMID). Arthritis Rheum 2002; 46: 3340-8.
7. AGOSTINI L, MARTINON F, BURNS K, Mc-DERMOTT MF, HAWKINS PN, TSCHOPP J: NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 319-25.
8. DINARELLO CA: Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355-9.
9. DINARELLO CA: The many worlds of reducing interleukin-1. Arthritis Rheum 2005; 52: 1960-7.
10. GOLDBACH-MANSKY R, DAILEY NJ, CANNA SW et al.: Neonatal-Onset Multisystem Inflammatory Disease responsive to interleukin-1β inhibition. N Engl J Med 2006; 355: 581-92.
11. HOFFMAN HM, THRONE ML, AMAR NJ et al.: Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrinassociated periodic syndromes: results from two sequential placebo-controlled Studies. Arthritis Rheum 2008; 58: 2443-52.
12. GOLDBACH-MANSKY R, SHROFF SD, WILSON M et al.: A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008; 58: 2432-42.
13. LACHMANN HJ, KONE-PAUT I, KUEMMERLE-DESCHNER JB et al.: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
14. KUEMMERLE-DESCHNER JB, HACHULLA E, CARTWRIGHT R et al.: Two year results from an open-label, multicentre phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011; 70: 2095-102.
15. IMAGAWA T, NISHIKOMORI R, TAKADA H et al.: Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol 2013; 31: 302-9.
16. LACHMANN HJ, GOODMAN HJB, GILBERTSON JA et al.: Natural history and outcome of systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-71.